HeartBeam, Inc.(BEAT)

Medical - Specialties · Santa Clara, CA

$0.65+0.22 (+50.53%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T12:50:40.653Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:50:40.653Z.

Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 36,312,572
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 8,722,000
TTM free cash flow · period ending 2026-06-30: -14,011,000

FMP input reference: a5ea7848df566bb1fba137e14a23bd7a424b67da13a14cf2752e181034030ce3

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BEAT EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

BEAT Competitors' EV/FCF Ratio

BEAT

HeartBeam, Inc.

Current

Market Cap

$36.31M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ELUT

Elutia Inc

vs BEAT

Market Cap

$36.32M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BCTX

BriaCell Therapeutics Corp.

vs BEAT

Market Cap

$36.37M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DCGO

DocGo Inc.

vs BEAT

Market Cap

$36.05M

EV/FCF Ratio

N/A

TTM Avg

1.82x

3Y Avg

3.39x

5Y Avg

16.62x

ELTX

Elicio Therapeutics, Inc.

vs BEAT

Market Cap

$36.61M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ARAY

Accuray Incorporated

vs BEAT

Market Cap

$35.89M

EV/FCF Ratio

N/A

TTM Avg

17.34x

3Y Avg

44.12x

5Y Avg

46.63x

EDSA

Edesa Biotech, Inc.

vs BEAT

Market Cap

$37.67M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HBIO

Harvard Bioscience, Inc.

vs BEAT

Market Cap

$38.34M

EV/FCF Ratio

N/A

TTM Avg

20.47x

3Y Avg

71.52x

5Y Avg

76.62x

GRCE

Grace Therapeutics, Inc.

vs BEAT

Market Cap

$33.52M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALGS

Aligos Therapeutics, Inc.

vs BEAT

Market Cap

$33.42M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
HeartBeam, Inc. (BEAT)	$36.31M	N/A	N/A	N/A	N/A
Elutia Inc (ELUT)vs ›	$36.32M	N/A	N/A	N/A	N/A
BriaCell Therapeutics Corp. (BCTX)vs ›	$36.37M	N/A	N/A	N/A	N/A
DocGo Inc. (DCGO)vs ›	$36.05M	N/A	1.82x	3.39x	16.62x
Elicio Therapeutics, Inc. (ELTX)vs ›	$36.61M	N/A	N/A	N/A	N/A
Accuray Incorporated (ARAY)vs ›	$35.89M	N/A	17.34x	44.12x	46.63x
Edesa Biotech, Inc. (EDSA)vs ›	$37.67M	N/A	N/A	N/A	N/A
Harvard Bioscience, Inc. (HBIO)vs ›	$38.34M	N/A	20.47x	71.52x	76.62x
Grace Therapeutics, Inc. (GRCE)vs ›	$33.52M	N/A	N/A	N/A	N/A
Aligos Therapeutics, Inc. (ALGS)vs ›	$33.42M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

BEAT EV/FCF Ratio Metrics

BEAT Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics